Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.61 |
| ▸ | MAOB | P27338 | 4/20 | 0.61 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.61 |
| ▸ | SDHA | P31040 | 2/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.61 |
| ▸ | CALML3 | P27482 | 1/20 | 0.61 |
| ▸ | F10 | P00742 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27707418 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL27875818 | 1.00 | MAOA (0.61) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7790986 | 0.92 | MAOB (0.53) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL28594529 | 0.90 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7537313 | 0.90 | MAOA (0.62) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7704124 | 0.90 | MAOB (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7157301 | 0.90 | MAOB (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6691779 | 0.90 | MAOB (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL7157296 | 0.90 | MAOB (0.49) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6687197 | 0.88 | F10 (0.48) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | DIPHARMA FRANCIS S.R.I. (IT) | 2009-06-18 | — | — | US | claimed |
| WO-2013072923-A1 | PROCESS FOR THE PREPARATION OF CRYSTALLINE LINEZOLID | CADILA HEALTHCARE LIMITED (IN) | 2013-05-23 | — | — | WO | disclosed |
| EP-2072505-B1 | A process for the preparation of oxazolidinone derivatives | DIPHARMA FRANCIS SRL (IT) | 2012-02-01 | — | — | EP | disclosed |
| US-7989618-B2 | Linezolid crystalline hydrate form and linezolid salts | DIPHARMA FRANCIS S.R.L. (IT) | 2011-08-02 | — | — | US | disclosed |
| EP-2174935-A1 | Linezolid Compositions | Teva Pharmaceutical Industries Ltd (IL) | 2010-04-14 | — | — | EP | disclosed |
| EP-2072505-A3 | A process for the preparation of oxazolidinone derivatives | Dipharma Francis S.r.l. (IT) | 2009-08-12 | — | — | EP | disclosed |
| EP-2072505-A2 | A process for the preparation of oxazolidinone derivatives | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | disclosed |
| EP-2072505-A2 | A process for the preparation of oxazolidinone derivatives | Dipharma Francis S.r.l. (IT) | 2009-06-24 | — | — | EP | disclosed |
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | DIPHARMA FRANCIS S.R.I. (IT) | 2009-06-18 | — | — | US | disclosed |
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | DIPHARMA FRANCIS S.R.I. (IT) | 2009-06-18 | — | — | US | disclosed |
| US-7291614-B2 | Processes for the preparation of linezolid intermediate | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2007-11-06 | — | — | US | disclosed |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | TEVA PHARMACEUTICALS USA, INC. | 2007-08-23 | — | — | US | disclosed |
| US-20070021417-A1 | Processes for the preparation of linezolid intermediate | TEVA PHARAMCEUTIALS USA, INC. | 2007-01-25 | — | — | US | disclosed |
| US-20060258655-A1 | Crystalline forms of linezolid intermediate | TEVA PHARMACEUTICALS USA, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060252932-A1 | Isolated bis-linezolid, preparation thereof, and its use as a reference standard | ENTIRE INTEREST | 2006-11-09 | — | — | US | disclosed |
| WO-2006091848-A9 | ISOLATED BIS-LINEZOLID, PREPARATION THEREOF, AND ITS USE AS A REFERENCE STANDARD | TEVA PHARMA (IL) | 2006-11-09 | — | — | WO | disclosed |
| WO-2006091731-A2 | PROCESSES FOR THE PREPARATION OF LINEZOLID INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-31 | — | — | WO | disclosed |
| WO-2006091777-A1 | CRYSTALLINE FORMS OF LINEZOLID INTERMEDIATE | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 2006-08-31 | — | — | WO | disclosed |
| US-20060142283-A1 | Crystalline form IV of linezolid | TEVA PHARMACEUTICALS USA, INC. | 2006-06-29 | — | — | US | disclosed |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | TEVA PHARMACEUTICALS USA, INC. | 2006-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156806-A1 | Process for the Preparation of Oxazolidinone Derivatives | OXA1L, AAAS, MLYCD | MAOA 466/4885MAOB 648/4885PTGS1 3485/4885 |
| US-20060142283-A1 | Crystalline form IV of linezolid | CYP4X1, MLX, CYP3A4 | MAOA 1716/4885MAOB 2041/4885PTGS1 4015/4885 |
| US-20070021417-A1 | Processes for the preparation of linezolid intermediate | CYP2C9, MRPL9, OXA1L | MAOA 649/4885MAOB 688/4885PTGS1 4398/4885 |
| US-20060111350-A1 | Solid forms of linezolid and processes for preparation thereof | F9, Q6ZSR9, TBCD | MAOA 1756/4885MAOB 2551/4885PTGS1 4164/4885 |
| US-20060252932-A1 | Isolated bis-linezolid, preparation thereof, and its use as a reference standard | FHIT, CYP2C9, CYP2C19 | MAOA 2591/4885MAOB 2182/4885PTGS1 4246/4885 |
| US-20070197529-A1 | Isolated desfluoro-linezolid, preparation thereof and its use as a reference marker and standard | MLLT3, DAO, FHIT | MAOA 1747/4885MAOB 2084/4885PTGS1 4548/4885 |
| US-20060258655-A1 | Crystalline forms of linezolid intermediate | EML4, MLLT3, OXA1L | MAOA 1298/4885MAOB 1529/4885PTGS1 4511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.